New Jersey Patent of the Month – April 2023
Abon Pharmaceuticals LLC has developed a long-acting injectable formulation of lurasidone that promises to revolutionize the treatment of schizophrenia and bipolar depression.
Schizophrenia and bipolar depression are chronic conditions that require consistent treatment. However, non-adherence to medication regimens is common, leading to poor prognosis and a host of other issues. The non-aqueous long-acting injectable formulation developed by Abon Pharmaceuticals addresses this issue by providing a predictable drug-release profile over a defined period of time following each injection.
Lurasidone is a highly effective atypical antipsychotic drug with low metabolic effects, unlike other atypical antipsychotics like clozapine, olanzapine, and quetiapine. However, its oral bioavailability is low, which limits its efficacy. Abon’s long-acting injectable formulation increases the bioavailability of lurasidone, which allows for lower dosing frequencies, improved efficacy, and reduced side effects. Additionally, the injection provides very high assurance of patient compliance and decreased incidence of side effects.
Abon’s team of scientists and chemists utilize advanced techniques and modern equipment to identify and characterize physicochemical properties essential to formulate and process complex dosage forms. Their long-acting injectable formulation of lurasidone offers an innovative solution to the challenge of non-adherence to medication regimens. By providing a predictable drug-release profile, increased bioavailability, lower dosing frequencies, and reduced side effects, it has the potential to improve the lives of millions of people suffering from schizophrenia and bipolar depression.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
